Insulin Resistance News and Research

RSS

Insulin Resistance is a condition in which the body does not respond to insulin properly. This is most common in Type II diabetes or associated with obesity, ketoacidosis, infection, and certain rare conditions. Diminished effectiveness of insulin in lowering blood glucose levels requiring 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

Many people who are overweight or obese develop insulin resistance and type 2 diabetes at some stage in their lives. A European research team has now discovered that obese people have large amounts of the molecule CXCL5, produced by certain cells in fatty tissue.

25 Nov 2009

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Researchers from the University of California, San Diego recently offered the sharpest-yet picture of how core biochemical pathways in skeletal muscle cells and fat cells are altered in people who suffer from insulin resistance-a primary defect in type 2 diabetes and obesity. Taking a systems biology approach, the bioengineers and medical researchers also determined how a common class of drugs for treating insulin resistance-TZDs-alter these same core pathways.

24 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Duke University and Jubilant Organosys Limited, the largest integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company in India, through its subsidiary, Jubilant Biosys Limited, today signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies.

11 Nov 2009

Environmental factors, obesity and diabetes: Long-term study launched

Three Singapore biomedical institutions have launched a major, long-term study of pregnant mothers and their fetuses as well as infant children to determine just how profoundly environmental factors early in life influence the onset of diseases such as obesity and diabetes in later years.

10 Nov 2009

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Compugen Ltd. announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes.

9 Nov 2009

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

The National Institutes of Health's National Heart, Lung, and Blood Institute will fund a $1 million collaborative study by the Center for Natural Medicine and Prevention at Maharishi University of Management Research Institute and Columbia University Medical Center to determine whether the stress-reducing Transcendental Meditation technique can help patients with coronary heart disease (CHD) prevent future heart attacks, strokes and death.

7 Nov 2009

Researchers use fruit fly model for diabetes research

As rates of obesity, diabetes, and related disorders have reached epidemic proportions in the US in recent years, scientists are working from many angles to pinpoint the causes and contributing factors involved in this public health crisis. While sedentary lifestyles and diets high in sugar and fat contribute significantly to the rise in diabetes rates, genetic factors may make some people more vulnerable than others to developing diabetes.

4 Nov 2009

Higher testosterone levels in older women are associated with increased health risks

Postmenopausal women who have higher testosterone levels may be at greater risk of heart disease, insulin resistance and the metabolic syndrome compared to women with lower testosterone levels, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

4 Nov 2009

Lap band surgery effective for morbidly obese adolescents, improves glucose metabolism

Washington, DC-A surgeon now at Children's National Medical Center and his colleagues from New York University have found laparoscopic adjustable gastric banding (Lap band) to improve the health of morbidly obese adolescents.

4 Nov 2009

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a randomized, double-blind, placebo-controlled Pilot Study of up to 165 persons who have type 2 diabetes, the most common form of diabetes.

2 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Metabolon raises additional $6 million in its Series C funding round

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today that it has closed an additional $6 million in its Series C funding round. This brings the total funding raised in the company’s series C round to $12.3 million.

27 Oct 2009

Studies highlight race- and gender-specific disparities in gastrointestinal disease

Three studies presented this week at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego underscore the growing disparities in gastrointestinal disease, particularly colon cancer and Barrett's Esophagus, among certain ethnic and gender populations, including African Americans, Latinos and women. These race- and gender-specific disparities underscore the need for education and vigilance among these populations and perhaps more aggressive screening tactics than the population in general.

27 Oct 2009

Football linemen at higher risk of future health problems

For today's athletes, size and strength can mean the difference between championships, scholarships and million-dollar paydays. But new research comparing the signs of metabolic syndrome in professional baseball and football players, presented at the American College of Gastroenterology's 74th Annual Scientific Meeting in San Diego, reveals that the larger professional athletes - specifically football linemen - may encounter future health problems despite their rigorous exercise routines.

27 Oct 2009

Heart attacks in middle-aged women more common, says study

Heart attacks appear to have become more common in middle-aged women over the past two decades, but all women and especially those younger than 55 have recently experienced a greater increase than men in their chances of survival following such a heart event, according to two reports in the October 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

Athletes may face future health problems despite their rigorous exercise routines, says study

26 Oct 2009

Exercise and lifestyle changes are key to improve heart health

Exercise is a wonderful way of boosting heart health, but it's proving to be a tough sell in Ontario South Asian communities, Dr. Milan Gupta told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Insulin Resistance News and Research

Further Reading

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Recent developments at Burnham Institute for Medical Research

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Environmental factors, obesity and diabetes: Long-term study launched

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

Researchers use fruit fly model for diabetes research

Higher testosterone levels in older women are associated with increased health risks

Lap band surgery effective for morbidly obese adolescents, improves glucose metabolism

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Metabolon raises additional $6 million in its Series C funding round

Studies highlight race- and gender-specific disparities in gastrointestinal disease

Football linemen at higher risk of future health problems

Heart attacks in middle-aged women more common, says study

Innovative approach to build a new drug to treat a number of CNS diseases

Athletes may face future health problems despite their rigorous exercise routines, says study

Exercise and lifestyle changes are key to improve heart health

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News